rss
Br J Ophthalmol 87:1497-1503 doi:10.1136/bjo.87.12.1497
  • Clinical science
    • Extended reports

Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study

Table 2

Results after 103Pd plaque for subfoveal neovascularisation

Eye number Vision (20/x) Follow up (months) Initial vision Last ETDRS vision Lines of vision Last reported vision Ophthalmic status
3 6 9 12 15 18 21 24 30 36 42 48 54 60 66 72 78 84
CF  =  counting fingers, LP  =  light perception, HM  =  hand movements, RR  =  radiation retinopathy; AMD  =  age related macular degeneration, PDT  =  photodynamic therapy, TTT  =  transpupillary thermotherapy.
1 400 400 400 400 400 400 320 320 250 250 250 400 400 NA NA NA CF 400 CF >−6 CF Regressed to dry AMD
2 63 40 32 32 32 32 NA 32 32 32 NA 32 40 40 32 32 63 32 3 32 Stabilised PED
3 40 63 63 40 63 50 40 40 40 63 NA 50 50 NA 200 NA 100 100 100 40 200 >−6 100 Eccentric recurrence at 82 months
4 250 200 200 400 320 320 320 100 100 400 200 80 80 63 63 250 63 6 63 Regressed to dry AMD
5 63 63 63 50 50 63 NA 80 63 40 40 50 NA NA 40 63 40 2 40 Regressed to dry AMD+
6 400 200 125 100 100 100 160 NA 100 125 200 250 250 640 NA NA CF CF CF 400 CF >−6 CF Improved but not dry
7 32 20 16 20 NA 25 25 32 32 32 32 32 63 400 NA CF 32 400 >−6 CF Regressed to dry AMD
8 40 25 160 250 250 NA 200 NA 200 400 400 400 CF NA CF CF CF CF 40 CF >−6 CF Regressed to disciform scar
9 40 40 NA 63 80 500 NA NA NA CF NA 400 400 40 400 >−6 400 Regressed to disciform scar
10 80 100 NA NA NA NA NA 400 160 CF 160 320 400 200 200 200 320 80 320 −6 320 Regressed to dry AMD
11 100 100 NA NA 100 NA NA NA NA NA NA HM HM 100 HM >−6 HM Vitreous haemorrhage at 24 months
12 160 80 63 80* 250* 200* 200* 250* 250* 250* 500* 400* 400* 400* NA LP* 160 500 >−6 LP SRN, re-irradiated at 9 months*
13 200 100 100 100 NA 63 NA 100 500 200 HM CF NA CF CF CF 125 HM >−6 CF Vitreous haemorrhage at 36 months
14 32 25 20 25 25 20 20 20 20 20 25 32 25 1 25 Regressed to dry AMD
15 50 100 63 100 125 160 200 200 200 250 320 400 CF 50 320 >−6 CF TTT given at 36 months
16 32 25 20 20 20 40 20 25 25 40 50 200 32 40 −1 200 PDT given at 30 months
17 50 32 32 20 25 50 25 NA 25 32 50 32 2 32 No progression
18 63 80 125 NA NA NA 250 250 250 500 63 500 >−6 500 Regressed to disciform scar
19 40 40 40 32 40 NA 50 50 160 320 CF 40 160 −6 CF PDT given at 24 months
20 125 100 125 125 200 320 400 200 200 CF 125 200 −2 CF PDT given at 24 months
21 100 100 100 100 125 125 NA 100 125 100 125 −1 125 No progression, deceased
22 50 63 50 63 100 100 125 250 320 320 NA CF 50 250 >−6 CF Regressed to disciform scar, deceased
23 32 63 63 100 100 160 200 125 32 125 −6 125 Progressed
24 100 100 100 125 125 125 NA 125 100 125 −1 125 Regressed to dry AMD
25 160 250 200 200 NA NA 200 200 160 200 −1 200 Improved but not dry, deceased
26 32 63 80 160 32 160 >−6 160 Progressed
27 50 100 160 400 NA NA NA NA HM NA HM HM HM CF 50 400 >−6 CF Regressed to disciform scar
28 63 50 32 63 32 3 32 Regressed to dry AMD
29 200 200 320 200 320 −2 320 Progressed, deceased
30 63 100 63 100 −2 100 Lost to follow up
31 125 25 125 25 >+6 25 Lost to follow up
Mean follow up (months) 33.3

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. Correct Author Email

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.